Physician profile
Eric Kossoff
NPI 1861439721
$36,661.98
in general payments reported to CMS, 2019-2025
14 companies · $2,750 in 2025
The $2,750 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,800 · 2020: $9,100 · 2021: $3,150 · 2022: $5,159 · 2023: $4,265 · 2024: $5,438 · 2025: $2,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,063 · Honoraria: $2,464 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Food and Beverage: $409 · Travel and Lodging: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,063.00 |
| Honoraria | $2,463.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Food and Beverage | $409.27 |
| Travel and Lodging | $267.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $9,240.00 | 2019-2022 | |
| Neuropace, INC. | $8,725.00 | 2019-2025 | |
| Greenwich Biosciences, INC. | $4,500.00 | 2020 | |
| Livanova USA, INC. | $4,098.65 | 2020-2023 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Biocodex, INC. | $3,347.38 | 2020-2023 | Diacomit |
| Gw Research Limited | $1,750.00 | 2021 | |
| Zogenix INC. | $1,400.00 | 2021 | |
| Otter Pharmaceuticals, LLC | $1,338.00 | 2024 | Sympazan |
| Shire North American Group INC | $1,200.00 | 2019 | |
| Neurocrine Biosciences, INC. | $600.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $269.74 | 2022-2023 | Epidiolex |
| Sk Life Science, INC. | $125.00 | 2024 | Xcopri |
| Eisai INC. | $49.72 | 2022 | |
| Ucb, INC. | $18.49 | 2023 | Fintepla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kossoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.